REVIEW PAPER
Innovative diabetes treatment in Poland - methods and costs
 
More details
Hide details
1
Akademia Humanistyczno-Ekonomiczna w Łodzi, Filia w Warszawie, Polska
CORRESPONDING AUTHOR
Waldemar Wierzba   

Akademia Humanistyczno-Ekonomiczna w Łodzi, Filia w Warszawie, Polska
 
Med Og Nauk Zdr. 2019;25(4):200–203
KEYWORDS
TOPICS
ABSTRACT
Diabetes mellitus is a common systemic metabolic disease associated with high healthcare costs. Type 2 diabetes is a problem worldwide and its doubling in the last 30 years is a fact. The occurrence of diabetes is positively correlated with the growing number of overweight and obesity patients. Currently, according to the International Diabetes Federation 2017, 415 million people have been diagnosed as adults with diabetes, and forecasts for 2040 state that there will be 642 million people with diabetes. An analysis of methods and costs of diabetes treatment in Poland was carried out in the years 2012–2015, which shows that we have a steady increase in expenditure on diabetes treatment in Poland. The presented studies concerned consumption and costs of therapies lowering blood glucose levels. The costs of drugs used to treat diabetes complications were not analyzed. It is known that the use of modern therapies (usually initially expensive) results in an improvement of patients’ health at a relatively higher initial cost. However, taking into account the distant effects, the economic calculus definitely shows the advantage of modern treatment over cheaper traditional therapies. Progress in medicine allows for personalization of treatment and selection of drugs for a specific target group; therefore,it is reasonable to make decisions on the reimbursement of new technologies, while maintaining precisely defined qualification criteria, which allows for a positive therapeutic and economic effect.
 
REFERENCES (12)
1.
Atlas IDF. International Diabetes Federation, 2017. Online version of IDF Diabetes Atlas: www.idf.org/diabetesatlas.
 
2.
Czeleko T, Śliwczyński A, Dziemidok P, Karnafel W. Cukrzyca znana w 2012 roku – ocena chorobowości na podstawie bazy danych Narodo- wego Funduszu Zdrowia (NFZ) – w środowisku wiejskim i miejskim. Medycyna Metaboliczna. 2017; 21 (1–2): 16–23.
 
3.
Czeleko T, Śliwczyński A, Dziemidok P, Karnafel W. Porównanie stosowania pasków do glukometrów u chorych na cukrzycę w populacji miejskiej i wiejskiej w Polsce: analiza danych Narodowego Funduszu Zdrowia obejmujących lata 2012–2014. Medycyna Metaboliczna. 2017; 21 (3–4): 29–36.
 
4.
Mokdad AH, Ford ES, Bowman BA i wsp. Prevalence of obesity, diabetes and obesity related health risk factors, 2001. JAMA. 2003; 289 (1): 76–79).
 
5.
Bray GA i wsp. Relation of central obesity and body mass index. Am J Clin Nutr. 2008; 87 (5): 1212–1218.
 
6.
Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroen- terology. 2007; 132 (6): 2131–2157.
 
7.
Drucker DJ. Enhancing incretin action for the treatment of the type 2 diabetes. Diabetes Care. 2003; 26 (10): 2929–2940.
 
8.
Pospisilik JA, Martin J, Doty T et al. Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats. Diabetes. 2003; 52 (3): 741–50.
 
9.
Aroor AR, Sowers JR, Jia G, DeMarco VG. Pleiotropic effects of the dipeptidylpeptidase-4 inhibitors on the cardiovascular system. Am J Physiol Heart Circ Physiol. 2014 Aug 15; 307 (4): H477–92.
 
10.
Marso SP, Daniels GH, Brown-Frandsen K i wsp. Liraglutide and Car- diovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016; 375:311–322.
 
11.
Zinman B, Wanner C, Lachin JM, Inzzucchi SE. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. New England Journal of Medicine; 373 (22). DOI: 10.1056/NEJMoa1504720.
 
12.
Śliwczyński A, Brzozowska M, Jacyna A i wsp. Drug-class-specific changes in the volume and cost of antidiabetic medications in Poland between 2012 and 2015. PLoS ONE. 2017; 12 (6): e0178764.
 
eISSN:2084-4905
ISSN:2083-4543